What’s Behind MannKind Corporation (MNKD)’s Incredible Run? – Pfizer Inc. (PFE)

Page 1 of 2

After seeing MannKind Corporation (NASDAQ:MNKD) rocket upwards over the last week, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about what’s going on with the inhaled insulin drugmaker.

Max Macaluso: It’s been an amazing week for biotech company MannKind. Shares were up more than 4% yesterday, and shares are up more than 30% in the last 5 trading days. Big jumps with small, volatile stocks like this can be common, but the company actually didn’t have any news or catalysts. What’s happening here?

MannKind Corporation (NASDAQ:MNKD)Brian Orelli: Options expire this week, and we’re hitting all-time highs in the Dow. Also they’re getting ready to selecting a new pope in Rome.

None of those have anything to do with MannKind Corporation (NASDAQ:MNKD)’s fundamentals, but I wouldn’t be surprised if they’re influencing the stock price — minus the last one, unless investors are hoping a needle-phobic diabetic pope could be MannKind’s next spokesman — biotechs move for strange reasons.

There’s no reason that MannKind should be moving up this week, but it’s not all that surprising that it’s moved off its lows. The biotech has been dead money since its last FDA rejection. At some point, it becomes worth waiting for.

Macaluso: Usually biotech stocks have a mind of their own and don’t necessarily move with the Dow, but let’s take a look at how the iShares NASDAQ Biotechnology Index‘s performance correlates with the Dow.

IBB Chart

IBB data by YCharts.

Orelli: Not that surprising. As the generalist investors get excited, the biotech investors get really excited. Unfortunately it works the same way on the way down, too.

Macaluso: So MannKind Corporation (NASDAQ:MNKD) is now perched on a 52-week high. Looking at their cash position, do you think the company needs to raise more capital with a follow-on public offering?

Orelli: Do we really need to look at their cash position? They’ve got a billionaire founder with so much tied up in the company, there’s no way Al Mann is going to let his namesake go out of business at this point.

Macaluso: Well, let’s say does Afrezza get rejected by the FDA again — do you think Mr. Mann will put more money into the company? I know I’d probably call it quits.

Orelli: Me too. But I think Mann is more stubborn than either of us. It obviously depends on the nature of the rejection. Unless it’s clear the FDA will never approve it, I think he sticks with it.

Macaluso: OK, let’s circle back to my previous question: Do you think now is a good time to raise capital with a follow-on public offering?

Orelli: In general, I think biotechs should raise money when they can, not when they need it. By that standard, hitting a 52-week high falls in the “when you can” segment.

But MannKind has already diluted the heck out of its shareholders. Shares outstanding at the company are up 59% since the end of 2010, before the latest FDA rejection. Put another way, a dollar of earnings that a share was entitled to in 2010 — assuming MannKind becomes profitable someday — is only worth $0.63 today.

So I guess my answer is no; MannKind Corporation (NASDAQ:MNKD) shouldn’t raise capital. If the upcoming clinical trials fail — probably unlikely, but anything’s possible — and the company runs out of money, so be it. It makes more sense to raise after the binary events, when the share price is hopefully higher and dilution won’t be quite as painful.

Macaluso: It can be dangerous to assume a drug will get approved because FDA decisions are unpredictable. Take Novo Nordisk A/S (ADR) (NYSE:NVO)‘s Tresiba, for instance. That drug was already approved in Europe and everyone believed it would be a shoo-in with the FDA, but it was handed a complete response letter.

Orelli: Yeah, buying after the run-up is almost never a good idea because in the risk-reward equation, you’ve lost some reward, but the risk is still the same.

Macaluso: So, Brian, what’s the next catalyst that investors need to watch?

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!